For Pharma & Biotech Executives

RSU Concentration Risk Analyzer

Your W-2 and your RSU stack are exposed to the same industry cycle. See your concentration number and what it would cost if your employer had a drawdown like its peers.

Your Position

$
$

Diversification Plan

$

Critical concentration

56.7%

of your liquid net worth sits in a single stock. Plus, your W-2 depends on the same sector performing well.

Downside Scenario

If PFE repeats its 5-year peak-to-trough drawdown of -58%:

RSU Value Loss

-$493,000

Simultaneously, sector-wide drawdowns often coincide with hiring freezes, bonus cuts, or layoffs — a double hit to both wealth streams.

Peer Group 5-Year Drawdowns

MRNA
-87%
BIIB
-68%
PFE
-58%
BMY
-50%
GILD
-48%
REGN
-45%

Diversification Glidepath

To bring concentration to a 20% target using vests alone:

10 quarters

Sell $56,250 at each vest. Reinvest into low-correlation assets — direct real estate and multifamily syndications are largely uncorrelated to pharma/biotech equity beta.

Get a diversification playbook

Tax-smart vest-sale sequencing + how to redeploy into uncorrelated assets.

Drawdown figures are illustrative peak-to-trough from public market data over rolling 5-year windows and are not predictions. Informational only — not investment advice. Consult a qualified advisor before selling RSUs or reallocating.

Talk through your numbers in 20 minutes

No pitch. I'll walk through how this fits your specific W-2, RSU, and household situation — and whether a syndication allocation even makes sense for you.

Book a 20-min call with David

— David Naccarato, Lucky Duck Group